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Individualized therapyColorectal tumours are actually considered as aberrant organs, within it is possible to
notice a different stage of cell growth and differentiation. Their origin is reported to arise
from a subpopulation of tumour cells endowed with, just like the healthy stem cells, self-
renewal and aberrant multi-lineage differentiation capacity likely to be called colorectal
cancer stem cells (CCSCs). Cancer stem cells (CSCs) fate, since their origin, reﬂects the inﬂu-
ences from their microenvironment (or niche) both in the maintenance of stemness, in pro-
moting their differentiation, and in inducing epithelial–mesenchymal transition,
responsible of CSCs dissemination and subsequent formation of metastatic lesions. The
tumour cells heterogeneity and their immuno-response resistance nowadays probably
responsible of the failure of the conventional therapies, make this research ﬁeld an open
issue. Even more importantly, our increasing understanding of the cellular and molecular
mechanisms that regulate CSC quiescence and cell cycle regulation, self-renewal, chemo-
taxis and resistance to cytotoxic agents, is expected to eventually result in tailor-made
therapies with a signiﬁcant impact on the morbidity and overall survival of colorectal can-
cer patients.
 2013 Elsevier Ltd. All rights reserved.Contents
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1. Introduction
Colorectal cancer (CRC) is one of the major causes of death worldwide (Jemal et al., 2011). Despite the prompt surgical
removal followed by adjuvant therapy, often suitable in the early stages of the disease, the majority of patients undergo
to recurrences andmetastases. This phenomenon frequently correlates with an acquired resistance to conventional therapies
such as chemo- and radio-therapy (Jänne and Mayer, 2000).
Increasing evidences recently claimed that tumours are structured by heterogeneous populations of cells hierarchically
organized, with CSCs at the top of this pyramid model. The concept that this subset of cells may arise from normal stem cells
(or progenitor cells), as a result of genetic and/or epigenetic mutations (Barker et al., 2009) is appealing for several reasons.
Healthy stem cells and CSCs share many properties, including the self-renewal and aberrant multi-lineage differentiation
capacity, altered DNA repair machinery, high expression levels of anti-apoptotic genes and ATP-binding cassette (ABC) trans-
porters, which could explain the failure of current anti-cancer treatments (Todaro et al., 2007). Moreover, the CSCs are highly
clonogenic and can generate a serially transplantable phenocopy of the primary malignancy in immuno-compromised mice
(Clarke et al., 2006), highlighting their tumourigenic capacity.
The amazing cellular turnover of the colon epithelium makes this tissue the ideal subject for the study on the healthy
stem cells biology, and then on cancer stems cells during tumour progression. Under physiological conditions, colon homeo-
stasis is highly regulated, and it is the result of a perfect balance between stem cells, differentiated cells and the microen-
vironment. Sometimes, however, this balance is missing, so throwing the foundations for the emergence and progression of
the tumour.
It has been noticed that the colon stem cells (SCs) reside at the base of the intestinal crypts, where the microenvironment
seems to orchestrate the stemness status, the proliferation and the resistance to apoptosis of stem cells, regulating different
signaling pathways. This network of signals link up different stromal cells, such as mesenchymal cells with immune cells,
blood vessels, soluble factors and extracellular matrix components (Kosinski et al., 2007) building the complex tumour archi-
tecture. Likewise the CSCs are strictly dependent from their residing environment, the tumour niche, which not only play a
role in determining the cell type, but also provides protection by sheltering CSCs from diverse genotoxic insults, contributing
to their enhanced therapy resistance (Sun and Nelson, 2012).
Most conventional therapies affect differentiated cells, which constitute the bulk of tumour mass, thus saving CSCs. This
phenomenon seems to be the cause of the initial tumour shrinkage followed by relapses, often more aggressive of the pri-
mary tumour of origin (Al-Hajj et al., 2004).
Nowadays, thanks to new quick and low-cost technologies, it is possible to achieve genomic and proteomic analysis to
better characterize the tumour patient ‘‘phenotype’’ considering that the ‘‘one-size-ﬁts-all’’ approach for cancer treatment
is not longer sufﬁcient. These ‘‘omics’’ analyses have pushed a new personalized approach in the cancer ﬁeld, trying to opti-
mize the treatment options, to avoid the resistance phenomena, bypassing unnecessary side effects (Chang et al., 2009; Wil-
son et al., 2007).
The origin and tumour progression are tightly regulated by aberrant oncogenic pathways activation, in concert with an
inactivation of tumour suppressor signals. This phenomenon, however, seems to follow a branched trend, rather than linear,
thus generating a large clonal diversity, and contributing to the intra-tumoral genetic heterogeneity (Marusyk et al., 2012).
The huge inter-tumour variability depends from several aspects, ﬁrst of all the variables related to the host (age, hormonal
status), while the intra-tumour cellular organization is differentially inﬂuenced by several stimuli coming from the contig-
uous microenvironment (differences in vascularity, inﬁltration degree, connective tissue components). Last but not least it is
also important to consider the cellular state diversity, as the cell cycle, the exposure to antigens, and the membrane com-
position (Heppner, 1984).
This great heterogeneity poses a considerable number of questions on how to address the issue of tumour, both from the
point of view of diagnosis and of the possible treatment suggested (Gerlinger et al., 2012), as we will discuss later in this
review.
We recent demonstrated the role of different components of the immune system against the tumours (Tallerico et al.,
2013; Todaro et al., 2009). Although there is strong evidence of how the cells of the immune system can limit tumour
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moting cancer growth and progression (Grivennikov et al., 2010; Shiao et al., 2011).
In spite of, it is evident that the tumour cells negatively regulate the immune system through the release of immunosup-
pressive factors (Sidler et al., 2011), and that the tumour inﬁltration by immune cells can be considered as a positive prog-
nostic factor for the overall patient’s survival (Pagès et al., 2010).
In light of the recent evidence, it will be interesting to deepening elucidate all the mechanisms regulating the immune
surveillance within the tumour microenvironment to develop important new therapeutic strategies to be coupled to conven-
tional therapies for better response to treatment.2. Colorectal cancer
CRC progression is characterized by the progressive acquisition of at least 4–5 oncogenes mutations, or of tumour sup-
pressor genes, determining a malignant tumour formation (Vogelstein et al., 1988), some of them occur often in the same
genes and are commonly shared by most people affected by this malignancy, otherwise some mutations are acquired differ-
ently and they determine the ﬁnal cancer phenotype (Fearon and Vogelstein, 1990).
Most of knowledge about colon cancer progression derived from the study of the its inherited form the familial adenoma-
tous polyposis (FAP), an autosomal dominant CRC syndrome caused by the Adenomatous Polyposis Coli (APC) gene mutation
which include about 10% of cases (Galiatsatos and Foulkes, 2006). The APC protein promotes theWnt signaling pathway acti-
vation, and its main role is in modulating the cytoplasmic B-catenin levels, a protein that migrating to the nucleus can acti-
vate the transcription of several genes involved in cell proliferation, differentiation, migration and apoptosis (Fearnhead
et al., 2001).
Tumour progression in these cases required also other related mutations such as KRAS, SMAD2/4, TP53 and deletion of
chromosome 18q (Kinzler and Vogelstein, 1996).Recent mounting evidences suggest that cancer growth is fuelled by a cell
subpopulation called cancer stem cells, not only important in establish the primary tumour but mostly in the metastatic pro-
cesses and tumour recurrences (Croker and Allan, 2008; Li et al., 2007b).
Tumour metastasis formation is a complex process that involves a sequence of pathological events, starting with local
invasion by tumour cells which must leave the primary tumour site, migrate through the blood and lymphoid vessels, to
evade from the circulation and reach the distant tissue, in order to form a micrometastasis. A study on melanoma cells
has shown that only 2% of these migrating tumour cells actually manage to form metastases to distant tissue (Luzzi et al.,
1998). According to this hypothesis, this number actually reﬂects the amount of CSCs within the tumour population.
It was recently noticed that CSCs as the metastatic tumour cells, need to be closely in contact with a speciﬁc microenvi-
ronment to support their growth and to provide protection and contrary to differentiated tumour cells the CSCs are resistant
to conventional therapies, (Lobo et al., 2007; Moitra et al., 2011), making them an ideal target to develop new therapy
strategies.3. Colon crypt and stem cells
Colon tissue is composed by the serosa, the muscolaris, the sub-mucosa and mucosa, as outer layer. It mainly consists of
epithelial and goblet mucipare cells and it is surrounded by an absorptive and secretory epithelium, folded in a set of invag-
inations (about 14,000/square centimeter in the adult human colon), called crypts of Lieberkuhn.
Each crypt contains about 2000/3000 cells, belonging to different populations: the columnar cells, the muco-secreting
goblet cells and a small fraction (about 1%) of entero-endocrine cells (Booth and Potten, 2000; Brittan and Wright, 2002).
According to the ‘‘unitarian theory’’ all these cell types are generated by a colonic SC (4–6 SCs/crypt), located at the base of
the crypt that, through an asymmetric division generate one stem cell (identical with self-renewal capacity) and one progen-
itor cell that can proliferate, differentiate and migrate to the top of the crypt (Cheng and Leblond, 1974; Kirkland, 1988;
Paulus et al., 1992).
Several markers have been linked to the colon SCs, among these: Musashi-1 (Msi-1), B lymphoma Mo-MLV insertion re-
gion 1 homolog (Bmi1), Aldehyde Dehydrogenase 1 (ALDH1), EphrinB (EphB) receptors, and Leuchin-rich repeat-containing
G protein-coupled receptor 5 (Lgr5).
Msi-1 is a RNA binding protein responsible for Drosophila melanogaster asymmetric division (Nakamura et al., 1994), it
was the ﬁrst molecule identiﬁed as a putative human colon SC marker. Its expression was reported in mouse small intestine
and in human colon crypt SCs (Nishimura et al., 2003; Potten et al., 2003). Msi-1 appears also to regulate p21 and Notch-1
signaling, as demonstrated by its silencing that causes mitotic catastrophe and xenograft tumour growth arrest by Notch
inhibition and p21 up-regulation (Sureban et al., 2008).
Another important putative marker for colon SC is Bmi-1 that has an crucial role in self-renewal of several tissues, as in
hematopoietic system, breast and neural one, and it is predominantly expressed in the small intestine at the base of the
crypts at the ‘‘+4’’ position, directly adjacent to the Paneth cells (Sangiorgi and Capecchi, 2008). Its expression marks the qui-
escent stem cells that proliferate in response to injury (Yan et al., 2012).
A more promising marker might be ALDH1, since its expression seems to correlate with the cells that exhibit stem cell
properties: a small subset of colonic cells are ALDH1+ (less than 5%), they localize at the bottom of normal colon crypts,
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et al., 2009).
It was recently demonstrated that colon SCs are marked by high expression of EphB2 receptor, which is gradually silenced
during cell differentiation (Merlos-Suárez et al., 2011). These important colon SC markers act regulating the migration and
proliferation in colon epithelium, and their expression follows a gradient along the crypt, with the highest levels at bottom of
the crypt, the so called ‘‘stem cell niche’’ (Holmberg et al., 2006).
In the same compartment at the base of crypt, some Lgr5 (Gpr49) positive cells were founded. Lgr5 is a trans-membrane
protein coupled with G-protein. In murine system, it is expressed only in active cycling columnar cells that can differentiate
into functional colonic epithelium lineages (Barker et al., 2007). Moreover it was recently demonstrated that a single Lgr5+
cell is able to regenerate a complete crypt-like structure in vitro (Sato et al., 2009). Moreover Lgr5 is a target gene of the well
deﬁned Wnt signaling pathway and its expression identify mitotically active stem cells important in the homeostatic regen-
eration of the tissue (Yan et al., 2012).
3.1. Stem cell niche
The organization of the intestinal niche includes ﬁbroblasts, endothelia and inﬂammatory cells, forming the appropriate
environment that guarantees the pluripotency of SCs.
The intestinal sub-epithelial myoﬁbroblasts (ISEMFs) are considered the most important players in the maintenance of
the niche, which surround the colon SCs, at the base of the crypt, regulate organogenesis and tissue repair. Their growth
is ﬁnely controlled by many factors that together with different cytokines maintain the ﬁne balance between self-renewal
and differentiation (Adegboyega et al., 2002; Powell et al., 1999).
We have recently demonstrated that the myoﬁbroblasts and their secreted factors, as well as hepatocyte growth factor
(HGF) have a key role in establishing the colon niche in colon crypts. We have shown that HGF can have an effect on differ-
entiated cells restoring their stem cell phenotype (Vermeulen et al., 2010).
In addition, current data show thatWnt, Phosphoinositide 3-kinase (PI3K), Bone Morphogenetic Protein (BMP), Notch and
Sonic Hedgehog (Shh) pathways are a prominent force controlling cell proliferation, differentiation and apoptosis along the
crypt-villus axis, thus maintaining stem cell fate and niche homeostasis.
3.1.1. Wnt pathway
In the last 20 years much it was published about the role of Wnt induced-signal in the regulation of colon tissue devel-
opment. The binding of Wnt ligands to their Frizzled receptors (Fz) prevents b-catenin degradation (by a complex containing
APC and Axin1/2), thus permitting its translocation to the nucleus where it acts as a transcriptional factor, interacting to the
TCF/LEF complex, and inducing several genes transcription involved in cell cycle regulation and proliferation (He et al.,
1998). An aberrant activation of this pathway, due to mutation in APC or b-catenin genes is clearly linked to colon cancer
development (Clevers, 2006).
The identiﬁcation of all the b-catenin target genes has led to the awareness about the role of this pathway in the main-
tenance of stemness, even if recent studies suggest that different cell types respond differentially to Wnt signal, according to
the cell localization along the crypt. In line with this model, it has also been demonstrated that there is a different expression
of Wnt members along the crypt: mRNA for secreted Fz-related proteins were found at the base of the crypts where they act
maintaining the cell stemness, otherwise their expression decrease toward the top of the crypt, where reside the differen-
tiated cells, and where are also expressed Wnt inhibitors (Gregorieff et al., 2005).
Moreover, the best characterized stemness target gene of Wnt/b-catenin pathway is Lgr5 (Barker et al., 2007), that such as
c-myc and cyclin D1, is involved in cell proliferation of the transit-amplifying compartment (He et al., 1998; Shtutman et al.,
1999; Tetsu and McCormick, 1999).
Furthermore the identiﬁcation of EphB as a Wnt target has improved our knowledge about the role of Wnt in the intes-
tinal morphogenesis regulation (Batlle et al., 2002), such as in the induction of epithelial differentiation and epithelial-
mesenchymal transition (regulating the expression of MMP7, laminin c2, Slug), important also for the tumour invasion
(Brabletz et al., 1999; Crawford et al., 1999; Hlubek et al., 2001; van Es et al., 2005).
Of course the effect of Wnt pathway is the result of a combined effect with all other actors of the colon stem niche.
3.1.2. Pten–PI3K–Akt pathway
A second important pathway with a central role in stem niche regulation is the PTEN–PI3K–Akt pathway. PI3K is com-
posed by the regulatory subunit p85 that can bind the receptor tyrosin-kinase (RTK), thus activating the catalytic subunit
p110, that can phosphorylate its substrates. This event leads to the phosphorylation of the Akt kinase (p-Akt) by PDK1.
PI3K pathway has just one negative regulator, the phosphatase PTEN, which convert PIP3 in PIP2, inhibiting Akt function
(Cully et al., 2006).
This pathway is important in stem niche regulation since is linked to theWnt one: p-Akt can phosphorylate b-catenin (He
et al., 2007), the main player of Wnt pathway, inducing its nuclear accumulation and enhancing its transcriptional activity
(Persad et al., 2001).
It seems indeed to be activated according to a gradient which shows the greater expression in the epithelial cells of the lu-
men,making guess that it could have a role in conﬁning the effect of theWnt pathway just in the colon crypts (Kim et al., 2002).
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and proliferation, in particular almost 40% of human colorectal cancer bring a constitutively PI3K activated pathway, mainly
due to PTEN inactivation (Parsons et al., 2005).3.1.3. BMP pathway
BMP pathway is a key regulator of colon cell differentiation (Auclair et al., 2007). BMPs belong to the Transforming
Growth Factor beta (TGF-b) super-family members, and after linking their receptor they can trigger different biological pro-
cesses (Chen et al., 1998). The activation of this pathway leads to the phosphorylation of Smad1, Smad5, and Smad8/R-Smad
(Miyazono et al., 2010) that in collaboration with the co-Smad, Smad4, translocate into the nucleus and regulate target gene
expression (Derynck and Zhang, 2003).
It was recently demonstrated (Kosinski et al., 2007; Rider and Mulloy, 2010) that there is a ﬁne distribution of the differ-
ent factors along the crypt: BMP1, BMP2, BMP5, SMAD7, BMP7 and BMP receptors are highly expressed in the apex of the
crypt, otherwise BMP antagonist, such as GREM1, GREM2 and chordin-like-1, are expressed at the base of the crypt (Hsu
et al., 1998), probably because of the presence of myoﬁbroblasts, which contribute to the stemness maintenance. Interest-
ingly it was shown that BMP pathway can control the number of colon SCs and their self-renewal (He et al., 2004).
There is a strong interaction between BMP with Wnt and PI3K pathway. In particular BMP inhibition by Gremlin leads to
the activation of Wnt (Kosinski et al., 2007), as well as BMPs stabilizes PTEN, leading to the Akt activity reduction and there-
by reducing b-catenin intranuclear accumulation (Persad et al., 2001; Waite and Eng, 2003).3.1.4. Notch pathway
The contribution of Notch signaling in colon SCs fate is extensively recognized by the scientiﬁc community. Notch path-
way consists of four different trans-membrane receptors (Notch1, Notch2, Notch3 and Notch4), and its activation is based on
the binding of ﬁve different ligands (Jagged-1, Jagged-2, Delta-like 1, Delta like 2 and Delta like 4). The ligands binding in-
duces the cleavage of Notch intracellular domain (NICD) mediated by ADAM metallo-protease. The NICD thus moves to the
nucleus where it activates the transcription of all its target genes after dimerization with RBP-jj/CSL (Dikic and Schmidt,
2010; van Es and Clevers, 2005).
The best characterized target gene of Notch pathway is the Hairy/enhancer-of-split (Hes-1) which is involved in the con-
trol of proliferation and differentiation (Bray, 2006).
Notch seems to push the proliferation of the transit-amplifying cells compartment, and its activity, in cooperation with
speciﬁc factors, is fundamental for the differentiation into several epithelial lineages.
Recent studies have shown how Notch and Math1 are essential for colon homeostasis and neoplastic transformation.
Moreover, the transgenic expression of the NICD blocks cell differentiation, through the expansion of immature progenitors
(Kim and Shivdasani, 2011; van ES et al., 2010).3.1.5. Hedgehog pathway
Sonic hedgehog (Shh) pathway is known to play an important role during colon development. Its activation is mediated
by the binding of Shh and Indian hedgehog (Ihh), which are secreted by epithelial cells, to its receptor Patched (PTCH), which
is expressed in the sub-epithelial myoﬁbroblasts. The activation leads to the release of the G-coupled protein Smoothened
(SMO) that, in collaboration with the GLI transcription factors, migrates into the nucleus to induce target genes activation
(Hegde et al., 2008).
The importance of this pathway is not directly the effect on epithelial cell fate, but in the correct development of crypts
and villi structures in the mucosa (Madison et al., 2005).4. Cancer stem cells
CSCs concept have been long discussed and investigated in the last years, furthermore also the term CSC was used many
times, often changing its meaning. For these reasons, during the Year 2011 Working Conference on CSCs, it was established
the correct deﬁnition of CSCs opening new questions on this regard (Valent et al., 2012).
It was established that CCSCs arise from the colon SCs, following genetic and/or epigenetic changes, sharing with them
several important properties such as the self-renewal and the aberrant multi-lineage differentiation capacity (Barker
et al., 2009). CCSCs are often less sensitive to conventional treatments than the bulk of differentiated cells from them gen-
erated, and this could be the reason of the initial regression of the tumour, often followed by a more aggressive relapse. An-
other important aspect in this ﬁeld is the continuing genomic and epigenomic changes that affect this population, thus
contributing to the resistance to standard treatments and then to the ampliﬁcation of such resistant clones (Baylin and Jones,
2011; Magee et al., 2012; Stratton, 2011). There are two major clinical issues about CSCs that we will try to deepen: the iden-
tiﬁcation and characterization of the CSCs, and the design of new target therapies against them.
The CSCs were isolated and characterized for the ﬁrst time from acute myeloid leukemia (Bonnet and Dick, 1997; Lapidot
et al., 1994), and then this concept has been extended to many solid tumours, including brain (Singh et al., 2004), head and
neck (Prince et al., 2007), pancreas (Li et al., 2007a), melanoma (Schatton et al., 2008), liver (Yang et al., 2008), lung (Eramo
Fig. 1. Heterogeneity of colon tumor initiating cells. Human colon cancer was considered composed by non tumorigenic cells and a small subfraction of
tumour-initiating cells (TICs) considered being a functionally homogeneous stem-cell-like population driving tumour growth and metastatic processes. This
schema report the recent evidences about cell heterogeneity in TIC compartment, containing three different cell subsets with different biological properties
and availability in primary tumour and metastasis. They include T-TACs and CSCs, these last can give rise to LT-TICs and DC-TICs.
66 S. Di Franco et al. /Molecular Aspects of Medicine 39 (2014) 61–81et al., 2008), prostate (Collins et al., 2005), ovarian (Curley et al., 2009), and colon cancer (O’Brien et al., 2007; Ricci-Vitiani
et al., 2007).
A recent study showed that within the tumour population it is possible to identify not only the CSCs and the differenti-
ated counterpart, but a more heterogeneous population with different biological properties (Dieter et al., 2011) Fig. 1.
Using a molecular tracking strategy and exploiting the tumorigenic ability by in vivo transplantation in immune-compro-
mised mice, Dieter et al. (2011) identiﬁed three different subtypes of colorectal tumour initiating cells (TICs) with different
roles on tumour growth and metastasis formation. The apex of the pyramidal model proposed is constituted by the self
renewing long-term TICs (LT-TICs), a cell subset that was founded both in primary and in serial tumours, and delayed con-
tributing TICs (DC-TICs), a cell population that was not detectable in primary tumours (probably due to their quiescent state)
but present in subsequent transplants. These two cell populations are identiﬁed as CSCs. The third tumour population, the
tumour transient-amplifying cells (T-TACs), was characterized by the ability to promote the primary tumour formation, but
without being founded in subsequent serial transplants (Fig. 2).
Nevertheless, the molecular mechanisms underlying the biological role of these different cell populations within the tu-
mour are still poorly understood.4.1. Colon CSC markers
Human CCSCs were ﬁrstly identiﬁed within the CD133+ population. CD133, also known as Prominin-1, is a glycoprotein
formed by a single polypeptide chain with a molecular weight of about 120 kDa with 20-kDa glycosidic-linked
Fig. 2. Biological roles of different subset of TIC during tumour progression. Schematic distribution of colon TICs in xenograft mouse model. Colon tumours
contain extensively self-renewing long term TICs (LT-TICs) that are able to maintain tumour formation in serial xenotransplants. Otherwise the tumour
transient amplifying cells (T-TACs) possess limited or no self-renewal capacity contributing just to tumour formation in primary mice. Rare delayed
contributing TICs (DC-TICs) were found only in secondary or tertiary mice. The metastasis formation seems to be driven by self-renewing LT-TICs
demonstrating that tumour initiation, self-renewal, and metastasis formation are limited to different subsets of TICs in primary human colon cancer.
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cellular loops, two intracellular domains and a cytoplasmic C-terminal domain (Yin et al., 1997).
Although its function is not yet well known, CD133 may regulate the cell polarity and cell–cell and cell–matrix interac-
tions (Giebel et al., 2004). Ricci-Vitiani et al. (2007) claimed that the CD133+ cell fraction is able to form tumour in vivo,
maintaining a self-renewal capacity after serial transplantations, otherwise CD133 fraction did not. CD133+ subpopulation
was also able to growth as spheres in undifferentiated state, preserving their capacity to differentiate when placed in serum
supplemented media.
Although this protein is widely considered to be a marker for the identiﬁcation of CSCs, its use it is still under debate as
demonstrated by several controversial results from different research groups (Shmelkov et al., 2008). Based on this obser-
vation it was suggested that CD133 cannot be considered a speciﬁc marker for CCSCs since its gene is widely expressed both
in undifferentiated and differentiated cells. It was also showed that both CD133+ and CD133 subpopulations obtained from
metastatic colon cancers are able to initiate tumour growth in in vivo transplantation experiments.
This discrepancy could be argued with the different glycosylation status (Kemper et al., 2010) and/or splice variants of
CD133 (Fargeas et al., 2004), or with the experimental methodology applied for protein detection, in particular regard cell
ﬁxing and/or permeabilization, which could modify the CD133 tertiary structure.
CD44 was recently described as another important marker for CCSCs identiﬁcation (Du et al., 2008). It is a cell-surface
glycoprotein involved in cell–cell interactions, cell adhesion and migration. Moreover, the existence of different splice vari-
ants (CD44v) of CD44 has gained a great interest since it was shown for the ﬁrst time their prominent role to confer a met-
astatic behavior to tumour cells. Furthermore the role of this molecule in tumour progression was demonstrated in many
cancers (Naor et al., 1997; Ponta et al., 2003). CD44 represents a family of glycoproteins encoded by a single gene that under-
go to the alternatively splicing giving rise to variable exon products (Screaton et al., 1992). Contrary to the ubiquitous
expression of standard isoforms (CD44s), CD44v aberrant expression was observed in many cancer types, conferring them
a metastatic potential, resulting in poor prognosis (Harada et al., 2001; Reeder et al., 1998; Wielenga et al., 1993).
CD44 is described as the main receptor of hyaluronan (HA), the most abundant component of the extracellular matrix,
highlighting its role as key regulator of cell adhesion (Aruffo et al., 1990). HA binding promotes cell motility and migration,
two paramount processes involved on tumour cells dissemination, extravasation of CSCs (Lamontagne and Grandbois, 2008),
and metallo-proteases production (Baronas-Lowell et al., 2004).
Finally several cytokines and chemokines such as Interferon gamma (IFNc) (Levesque and Haynes, 2001), osteopontin
(Kazanecki et al., 2007), Hepatocyte Growth Factor (HGF) (Corso et al., 2005), basic Fibroblast Growth Factor (bFGF) (Bennett
et al., 1995), Vascular Endothelial Growth Factor (VEGF) (Tremmel et al., 2009), heparin binding factor (Yu et al., 2002), can
also bind CD44 with important implications in cell proliferations and survival.
Among the all splice variants of CD44, CD44v6 boast of a central role in metastatic progression and its expression was also
associated with poor prognosis in CRC (Peng et al., 2008; Zlobec et al., 2009). CD44v6 is primary involved in the assembly of
the matrix, supporting its function in tumour cell cross-talk with the stroma and in pre-metastatic niche formation.
Many other CSC markers have been proposed including CD24 (Choi et al., 2009), ALDH1 (Huang et al., 2009), MSI1 (Potten
et al., 2003) and CD29 (Vermeulen et al., 2008). Farther, several studies showed that the CCSCs could reside within different
cell subsets, such as in the EpCAMhi/CD44+ fraction (Dalerba et al., 2007).
However it is common opinion that the cancer stemness is linked not to the exclusive expression of one of these markers
but to a combined expression of them. For this reason our group decided to re-examine the expression of these markers:
using the single cell sorting we found that the clonogenic potential resided in the CD133+ population which co-expressed
the other CCSC markers mentioned above (Vermeulen et al., 2008).
Fig. 3. Colon cancer progression. The formation of metastasis is considered a multistep cell-biological process that involves the dissemination of colon CSCs
to anatomically distant organs and the following adaptation and growth in the foreign microenvironment. All these events are driven by the acquisition of
genetic and/or epigenetic changes of tumour cells and the cooperation of non-neoplastic stromal cells. The ﬁrst step consists of the local invasion of colon
cancer cell through the EMT. The surviving cancer cells then produce exosomes and other soluble factors that can have an important role in determining the
pre-metastatic niche. In the last step the cancer cells have to arrest at the target organ and to become proliferative active through the MET, to ﬁnally form
clinically detectable macro-metastases.
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It is widely accepted that the SCs need a stem cell niche for their maintenance, to control the correct balance between
survival, self-renewal and differentiation programs (Morrison and Spradling, 2008).
This concept was also extended to the CSCs population, and convincingly demonstrated mostly during the metastasis for-
mation processes (Bissell and Labarge, 2005).
According to the ‘‘seed and soil’’ theory the organ-preference patterns of tumour metastasis result in interaction between
metastatic tumour cells and their speciﬁc microenvironment. More recently, it has been suggested that early changes in the
microenvironment at the distant sites, could be induced by the primary tumour, reported as ‘‘pre-metastatic niche’’ forma-
tion, although the mechanisms and factors responsible for such pre-metastatic niches are not well deﬁned (Kaplan et al.,
2005).
Over recent years, there has been an appreciable increase in our understanding of the cross-talk that occurs between
these two compartments on the systemic, cellular, and molecular bases. Continued investigations of the mechanisms that
mediate site-speciﬁc metastasis and new insights to the differences between the normal and CSCs niches will likely lead
to the identiﬁcation of new targets for therapy.
4.2.1. Exosomes
As previously mentioned, the CSCs to form metastasis need to be supported by an educated environment necessary to
lead extravasation, to implant and grow driven also by soluble factors, recently found likewise within the exosomes which
assume on this context a decisive role.
Exosomes are small vesicles of 30–100 nm (Johnstone, 2006) generated upon fusion of multivescicular bodies (MVB) with
the plasma membrane (Lakkaraju and Rodriguez-Boulan, 2008), their importance in cancer comes from their biological role
and from the evidence that cancer cells release more exosomes than the normal cells (Johnstone, 2006).
The exosomes content is related to their cell of origin, such as the function of the protein there harbored, that is main-
tained over time (Schorey and Bhatnagar, 2008).
Exosomes contain a big set of both membrane and cytosolic molecules including integrins, ICAM, Major Histocompatibil-
ity Complex (MHC) molecules, vesicle transport associated proteins, Heat Shock Proteins (HSPs), signal transduction mole-
cules, and tetraspanins (Gruenberg and Stenmark, 2004). Tetraspanins seem to have a key role in both the mechanisms that
regulate the exosomes function, the selective proteins recruitment into exosomes, and the following interaction with the tar-
get cells.
Tetraspanins are a family of 34 proteins with four intramembrane domains (Boucheix and Rubinstein, 2001), which form
a network with other transmembrane and intracellular signaling proteins (Levy and Shoham, 2005). Among their partners
there are G protein coupled receptors (Little et al., 2004), peptidases (Le Naour et al., 2006), Ig superfamily members and,
mostly important in CRC, CD44v6 and EpCAM (Kuhn et al., 2007). All these associated partners highlight the tetraspans
as an important factor in the regulation of cell motility, adhesion, and invasion.
Furthermore, it has been assed that exosomes hold different mRNAs and miRNAs, which can be in turn transferred to the
target cells, thus activating several pathways (Baj-Krzyworzeka et al., 2006). Based on this observation a higher concentra-
tion of exosomal mRNAs was indeed found in the serum of CRC patients (Fleischhacker and Schmidt, 2007), enriched in
cell-cycle related mRNA leading to endothelial cell proliferation, suggesting their potential involvement in tumour growth
Table 1
Colon cancer staging.
AJCC stage TNM stage TNM stage criteria for colon cancer
Stage 0 Tis N0 M0 Tis: tumor conﬁned to mucosa; cancer-in situ
Stage I T1 N0 M0 T1: invasion of submucosa
Stage I T2 N0 M0 T1: invasion of muscularis propria
Stage II-A T3 N0 M0 T3: invasion of subserosa or beyond (without other organs involvement)
Stage II-B T4 N0 M0 T4: invasion of adjacent organs or perforation of the visceral peritoneum
Stage III-A T1-2 N1 M0 N1: metastasis to 1 to 3 regional lymph nodes. T1 or T2
Stage III-B T3-4 N1 M0 N2: metastasis to 1 to 3 regional lymph nodes. T3 or T4
Stage III-C Any T N2 M0 N2: metastasis to 4 regional lymph nodes. Any T
Stage IV Any T Any N M1 M1: distant metastases. Any T, any N
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which are down-regulated, suggesting a tumour suppressor role. For this reason improvements on exosomal mRNA and miR-
NA proﬁle characterization would be suitable to use as prognostic factor (Taylor and Gercel-Taylor, 2008; Tokarz and Blasiak,
2012).4.3. EMT and MET in colon cancer progression
Metastases formation is the ﬁnal product of a multistep process, which involves the dissemination of cancer cells to dis-
tant organs and the following adaptation and proliferation into the foreign tissue microenvironment. This process is deter-
mined by the genetic and/or epigenetic alteration of cancer cells, but also driven by non-neoplastic stromal cells (Valastyan
and Weinberg, 2011).
The epithelial-mesenchymal transition (EMT) has been noticed as the ﬁrst step of the metastatic cascade as a well deﬁned
biological event playing an important role not only in normal tissue development during the organogenesis, but also in the
pathogenesis of diseases, with particular interest during the acquisition of the migratory phenotype of CRC cells (Thiery
et al., 2009).
Cells that undergo to EMT are characterized by loss of some epithelial features, such as the apico-basal polarity and
cell adhesion, the expression of E-cadherin, occludin and cytokeratins, and at the same time a marked up-regulation of
N-cadherin, vimentin, ﬁbronectin, Twist1, zinc-ﬁnger proteins (SNAIL, SLUG, ZEB2) and metalloproteinases, with consequent
increase of cell mobility (Lee et al., 2006).
A paramount of different signals directly from the surrounding microenvironment may lead to the acquisition of an inva-
sive phenotype in epithelial malignancies (Le et al., 2008), i.e. ﬁbroblasts, myoﬁbroblasts, granulocytes, macrophages and
lymphocytes are deﬁned as EMT-inducing factors: pathway as TGF-b (through the direct activation of Twist, SLUG and
ZEB2), PI3K/Akt (increasing the mTOR kinase expression), Shh and Wnt are indeed potent inducers of EMT (Gulhati et al.,
2011; Moustakas and Heldin, 2007).
Furthermore, the mesenchymal-epithelial transition (MET), the reverse process to EMT, is also considered as fundamental
mechanism occurring in normal tissue development and in colon mucosa regeneration. This process could play a role both in
the ﬁrst steps of tumour formation, since a dedifferentiation process of the mesenchymal cells is suggested to be crucial in
some cancers (Rubio et al., 2008), and in metastasis formation (Brabletz, 2012).
Despite considerable studies in cancer, to date there is not a reliable theory underling the mechanisms regulating the
migrating cancer stem cells (mCSCs) (Brabletz et al., 2005) and the acquisition of the metastatic phenotype of tumour cells
opening a new issue on tailored therapy Fig. 3.5. Treatment option overview
A key role in the cure of colon cancer is represented by the prevention, followed by the surgery when the tumour is still in
the early stages of development. This approach offers to the patients a good rate of success but unfortunately the symptoms
of early disease, such as fecal occult blood (FOB), occur just in 5% of the cases.
Nowadays there are two strategies available for colon cancer screening: the fecal occult blood test (FOBT) and the colon-
oscopy, these analyses are suggested to be addressed to over-50 years old men and women every 1–2 years.
An important serological marker for early detection and diagnosis for colorectal cancer is the carcinoembryonic antigen
(CEA), which can be used in the preoperative staging and postoperative follow-up, even if it possesses a poor predictive value
in asymptomatic patients because of the low sensitivity and speciﬁcity (Labianca et al., 2010).
Table 1 shows the different colon cancer stages according to the American Joint Committee on Cancer (AJCC) and the TNM
Classiﬁcation of Malignant Tumours (TNM).
Colon cancer staging it is useful for diagnostic and essential to determine the best treatment. As showed in Table 1, the
staging depends on the local invasion extension, the degree of lymph node involvement and distant metastasis. For the
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course the deﬁnitive classiﬁcation can only be determined after surgery, and pathology analysis.
The standard treatment for metastatic CRC (only about 39% of them are found at an early stage) is represented by a com-
bination of 5-ﬂuorouracil, leucovorin and oxaliplatin (FOLFOX), or a combination of 5-ﬂuorouracil, leucovorin and irinotecan
(FOLFIRI). These regimens are actually used more frequently in younger than older patients with metastatic CRC, maybe to
improve the resection rate (Lenz, 2008).
In order to reduce the risk of relapses, the standard of care for patients with early-stage CRC remains the surgery, com-
bined with adjuvant chemotherapy (most of them are given for about 6 months).
Adjuvant therapy is generally used in cases of high risk, deﬁned by the serosa inﬁltration of tumour (stages II B, III and IV).
Patients with stage II A can be considered at high-risk if there is a poorly differentiated tumour, or more than 12 lymph nodes
involved, or with a vascular/lymphatic invasion, or tumour perforation.
The inﬁltration of tumour cells in regional lymph nodes is today considered as the most accurate prognostic factor for
colorectal cancer survival (Iddings and Bilchik, 2007).
CRC staging is useful not only for the prognosis but also to predict which patients will beneﬁt from adjuvant therapy. The
chemotherapy administered after surgery at stage III colon cancer patients improves their survival, enhancing both the time-
to-recurrence up to 40% and the overall survival (OS) up to 30% (Krook et al., 1991; Wolmark et al., 1993).
CCSCs seem to resist death-inducing signals thanks to their slow cycling proliferation and to high levels of drug transport-
ers (Dean et al., 2005). CCSC are also characterized by high levels of anti-apoptotic proteins and it makes them resistant to
apoptotic stimuli (Todaro et al., 2008).
After chemo- or radio-treatments, these drug-resistant cells are responsible of the repopulation of treated-tumours, for
this reason the identiﬁcation and targeting of the characteristic pathways of this cell subset, such as of the microenviron-
ment in which they reside could be important to completely eradicate the tumour.
5.1. Targeted therapy: how to selectively kill CCSCs?
CCSCs constitute a minority cell subset in the tumour bulk and they are considered to be the source of tumour cell renew-
al, thus affecting the tumour behavior in terms of cell proliferation and resistance to chemo- and radio-therapy.
Their ability to survive to conventional therapy is due to the over-activation of some signaling pathways (EGFR, VEGF,
Wnt, Notch) and to the effect of the microenvironment in which they reside and growth.
For these reasons the molecular targeting of such highly tumorigenic cells must be considered the key to improve the
efﬁcacy of current anti-cancer strategies, aiming to sensitize tumours to conventional therapies thus deﬁnitely abrogate
tumorigenesis.
5.1.1. CSCs targeting
Conventional therapies most of the times do not sufﬁce in killing all tumour cells, since they affect the more differentiated
cells (which constitute most of the tumour mass) thus saving the CCSCs, which are then able to repopulate the tumour bulk.
This is mainly due to the quiescent state of CCSCs that protect them against conventional treatment, which mostly target
active proliferating cells.
For this reason one of the most promising treatments that could be coupled to conventional ones is the differentiation
therapy. The induction of differentiated state could force the CCSCs to acquire a mature phenotype, thus making them more
vulnerable to standard therapies. In this regard Lombardo et al. (2011) have recently demonstrated that BMP4 can promote
terminal differentiation, apoptosis, and chemosensitization of CCSCs, suggesting that BMP4 might be considered as a ther-
apeutic agent against CSCs in advanced colorectal tumours.
Since the CCSC state is a consequence of the EMT process, another therapeutic approach could involve the use of EMT
inhibitors, by blocking TGF-b and Wnt signaling, which are the most characterized pathway known to positively affect this
process (De sousa et al., 2011; Thiery et al., 2009).
A recent work revealed that CCSCs (identiﬁed as CD133+ cells) produce and utilize IL-4 to protect themselves from cell
death. Consistently to these data, the treatment with IL-4Ra antagonist or anti-IL-4 neutralizing antibody showed a sensiti-
zation of this cell subset to chemotherapeutic agents, paving the way for the development of new CCSCs target treatments
(Todaro et al., 2007).
Finally, an important difference between normal and cancer cells is about their metabolism, the so-called Warburg’s ef-
fect. Warburg et al. (1927) reported an increased uptake of glucose and production of lactate by tumours in vivo as compared
with normal tissues.
This study suggests that cancer cells restrict use of fatty-acid oxidation in favor of glycolysis as an ATP energy source and
even if this concept was recently revised (Koppenol et al., 2011), it could be exploited for therapy (Dang et al., 2011).
5.1.2. Targeting CCSCs pathway: VEGF
It is widely accepted that tumour growth is supported by a framework of new blood vessels, in a process called angio-
genesis, which does not occur in the normal healthy tissues except for tissue repair, remodeling or inﬂammation (Kerbel,
2008).
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new or extended capillaries, involving many processes such as vasodilation, vessel permeability, and endothelial cell prolif-
eration and migration.
The interplay between CSCs and vasculature was clearly demonstrated by Bao et al. (2006). In this study it is shown how
the CD133+ cells give rise to strongly angiogenic tumours compared to CD133- cell subset. This effect can be explained by a
10–20-fold increase in VEGF release of these cells of CD133+, giving them a signiﬁcant angiogenic advantage.
The correlation between CSCs and tumour vascularization was also demonstrated by Folkins et al. (2009), who showed
that CSC-high tumours exhibited increased microvessel density and blood perfusion compared with CSC-low ones, also
inducing increased mobilization and tumour recruitment of bone marrow-derived endothelial progenitor cells (EPC).
Recent ﬁndings showed that also the endothelial cells have an effect on CCSCs. Lu et al. (2013) indeed described how the
endothelial cells through paracrine signaling can induce colorectal cancer cells to acquire CSCs properties, in terms of
CD133+/ALDH1+ compartment and sphere forming capacity, and that this conversion is mainly mediated by Notch pathway.
Together these data suggest that CSCs can be the most important source of angiogenic factors in tumour microenviron-
ment and that the targeting of pro-angiogenic factors could be critical for patient therapy.
In this regard a recent work by Blansﬁeld et al. (2008) showed that the targeting of tumour microenvironment, in partic-
ular toward endothelial cells and inhibition of angiogenesis, could be considered a promising therapy to apply in clinic. In
this work it was demonstrated how lenalidomide, sunitinib (both involved in inhibition of angiogenesis, through different
mechanisms) and cyclophosphamide (cytotoxic to endothelial cells) were able to inhibit the proliferation of endothelial cells
in vitro (in an additive manner) and to completely inhibit the in vivo growth of primary tumour in mouse models. Tumour
growth inhibition is due to the ability of these compounds to establish an inhospitable tumour microenvironment (Blansﬁeld
et al., 2008).
Among molecules that regulate tumour angiogenesis, the most characterized pathway involves VEGFs and receptors
(VEGFRs), even if it can be also regulated by many other factors as platelet-derived growth factor (PDGF), FGF and transform-
ing growth factor alpha (TGF-a) (Hicklin and Ellis, 2005).
The VEGF family encloses six members: the most important is VEGF-A, then the placenta growth factor-1 and -2 (PGF-1,
PGF-2), VEGF-B, VEGF-C and VEGF-D. All these molecules are soluble factors secreted by tumour and stromal cells that bind-
ing the extracellular domain of their receptors leading to several intracellular signaling cascades endowed with survival, pro-
liferation, migration, differentiation and permeability of endothelial cells.
It was assessed that the VEGF expression may play an important role in human colon cancer progression, in particular
during the transition from premalignant adenoma to invasive and metastatic disease (Takahashi et al., 2003). Its over-
expression it is correlated with tumour progression and a worse prognosis (Lee et al., 2000).
Judah Folkman in 1971 for the ﬁrst time proposed a possible key role of angiogenesis in tumours, farther suggesting the
anti-angiogenic agents as potential compound for cancer treatment (Folkman, 1971).
Many molecules have been tested and undergone to clinical trials, and among these the bevacizumab, a monoclonal anti-
body directed against VEGF-A was the ﬁrst successfully accepted, in 2004, to use in combination with standard chemother-
apy for metastatic CRC inhibiting angiogenesis and thus the tumour growth (Gordon et al., 2001).
It is also functional in normalizing the tumour blood vessels structure, decreasing the intra-tumour hydrostatic pressure,
enhancing the drug delivery to the tumour (Ellis, 2006).
The bevacizumab was initially use in combination to the IFL (irinotecan, 5-FU and leucovorin) (Hurwitz et al., 2004), and
then to other regimens, in many of which it resulted fundamental for increased response rates (RR) and survival rate
(Grothey et al., 2008).
Two studies also analyzed its possible negative effect on postoperative wound healing in patients were subjected to he-
patic resection, both demonstrating no increase complications upon patients treatment (Gruenberger et al., 2008; Kesmodel
et al., 2008).
Unfortunately some important side effects were observed, such as gastrointestinal perforation (1.5%), arterial thrombosis,
myocardial infections and strokes (Prat et al., 2007).
Even if the inhibition of angiogenesis has been emerging as an efﬁcient strategy for treating CRC, recurrences often occur
after the ﬁrst period of suppression of tumour growth. Moreover some anti-angiogenesis drugs have been shown to posi-
tively inﬂuence metastasis of malignant progression in animal models (Ebos et al., 2009; Pàez-Ribes et al., 2009).
In a recent study it was shown that CCSCs (CD133+ cells) are more resistant to anti-angiogenesis treatments, and this
could be the reason of the occurring of recurrences after this treatment. This phenomenon is mediated by the activation
of anti-apoptotic signaling pathway involving Hsp27, and its inactivation can sensitize CCSCs to undergo cell death (Lin
et al., 2013).
5.1.3. Targeting CCSCs pathway: EGF
As previously mentioned the CCSCs require the presence of growth factors produced by the microenvironment for their
proliferation and maintenance of stem-like properties (Vermeulen et al., 2010). One of the best characterized factors that
affect CCSCs behavior is the Epidermal Growth Factor (EGF), which is known to regulate intestinal epithelial cell and
stem/progenitor cell growth and differentiation (Suzuki et al., 2010). In a recent study Feng et al. (2012) showed that EGF
signaling activation is necessary to promote the formation of CCSCs and for their maintenance of self-renewal capacity.
For these reasons EGF receptor (EGFR) became an important possible target in cancer therapy.
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Erb3 (HER3) and Erb4 (HER4). Upon activation by binding of its growth factor ligands EGF and TGF-a, EGFR switch from an
inactive monomeric form to an active homo- or hetero-dimeric complex resulting in the stimulation of its intrinsic intracel-
lular protein-tyrosine kinase activity, determining an auto-phosphorylation of several tyrosine residues in the C-terminal
domain. Receptor activation, through the docking of cytoplasmic proteins, can initiate several cell signaling pathways,
including the Ras–Raf–MAPK, PI3K/Akt, the protein kinase C, STAT and src kinase pathway, primarily involved in cell prolif-
eration, inhibition of apoptosis, invasion and migration.
Nowadays, two different anti-EGFR therapies are currently use for colorectal cancer treatment, the Cetuximab, a mono-
clonal antibodies that recognize EGFR (a partially humanized monoclonal antibody) (Van Cutsem et al., 2009), or pani-
tumumab (a fully human monoclonal antibody) (André et al., 2013), and small molecule inhibitors of EGFR tyrosine
kinase activity (TKIs) (Marshall, 2006).
The monoclonal antibody cetuximab prevents receptor activation interfering with its dimerization through steric inhibi-
tion of the extracellular domain, leading also to receptor internalization and subsequent degradation. Moreover cetuximab
can kill target cells by mediating antibody-dependent cell- mediated cytotoxicity (ADCC) and complement ﬁxation
(El Zouhairi et al., 2011).
On the contrary panitumumab blocks ligands binding determining receptor internalization, but without induced degra-
dation, suggesting that it could be recycled to the cell surface.
cetuximab was approved by the US Food and Drug Administration (FDA) in February 2004, in combination with irinotec-
an in irinotecan-refractory patients, or as a single agent in patients intolerant to irinotecan. It was tested both alone in pa-
tients that were refractory to irinotecan-containing regimens, inducing a response in 10.8% of them with a media time to
progression (TPP) of 1.5 months, and in combination with irinotecan, obtaining 22.9% of response and a TPP of 4.1 months
(Cunningham et al., 2004).
Panitumumab obtained the FDA approval based on similar studies, reporting an 8% of response in patients whose disease
had progresses after FOLFOX and FOLFIRI regimens (Douillard et al., 2010; Gibson et al., 2006; Peeters et al., 2010; Van
Cutsem et al., 2007).
The more investigated TKIs targeting EGFR for metastatic CRC are geﬁtinib, erlotinib, and EKB-569. Their activity in met-
astatic CRC was minimal, and in combination with FOLFOX and FOLFIRI the clinical response rate ranged from 24% to 74% in
phase II studies. The worse aspects in the use of TIKs were the adverse effects, with a 3–4-fold increase grade of toxicity.
Probably the most interesting aspect of the anti-EGFR therapies is the role of mutant Kras in predicting response to these
treatments. Kras is a small intra-membrane serine–threonine kinase, activated just downstream of EGFR, which acts prop-
agating further signaling events.
Retrospective studies for both cetuximab and panitumumab, showed that there is a strong correlation between Kras sta-
tus and the response to these treatments. Lièvre et al. (2008) demonstrated for cetuximab treatment that in the mutated Kras
tumours the response rate was of 0% versus the 40% in the tumours with wild-type Kras, with an increased overall survival of
4 months in the latter (Lièvre et al., 2008).
A similar study was performed for panitumumab treatment, where the researchers showed that no mutated Kras tu-
mours responded to panitumumab, versus the 17% of responding patients with wild-type Kras (Amado et al., 2008).
As a consequence of these ﬁndings all the clinical trials for anti-EGFR treatments have to take in consideration the muta-
tional status of Kras.6. Immune system, tissue homeostasis and colon cancer development
The main role of the immune system is to maintain the tissue homeostasis, to protect against pathogens and to eliminate
damaged cells.
In this context the tumour is a disease that arises from DNA mutations affecting crucial pathways that regulate cell pro-
liferation, survival and cell death, impairing the tissue homeostasis. The aberrant tissue homeostasis was recently addressed
as new ﬁeld of study drawing complicate and multifunctional network between the microenvironment and tumour cells, in
favor of the survival of the latter. Based on this observation the immune microenvironment could play a key role during the
tumour progression.
The mammalian immune system is made up of different cell types (innate or adaptive immunity) and mediators, which
interact with non-immune cells to create a dynamic network of signals thus providing protection against pathogens, while
ensuring tolerance to the self-antigens.
The ﬁrst-line of protection against perturbations in tissue homeostasis is represented by sentinel macrophages and mast
cells which through the release of soluble mediators, such as cytokines, chemokines, matrix remodeling proteases and reac-
tive oxygen species (ROS), attract additional leukocytes into the damaged area.
The dendritic cells (DCs) interconnect directly the innate and the adaptive immunity capturing the foreign antigens and
presenting them to the adaptive immune cells into lymphoid organs. Also the natural killer cells (NKs) partecipate to the
cross-talking between innate and adaptive immune cells interacting with the DCs, eliminating them or promoting their mat-
uration (Hamerman et al., 2005; Raulet, 2004).
Fig. 4. Dual roles of innate and adaptive immune-cells and their released factors in colon cancer development and progression. The immune system
possesses dual and controversial role regard cancer progression and the ﬁnal result of its function seems to be caused by the correct balance of all its
components. When cancer cells are recognized by the immune system the antigens that are present in early neoplastic cells are transported by dendritic
cells (DCs) to lymphoid organs where they lead to the activation of adaptive immune cells, thus resulting in both promoting and counteracting tumour
growth. The activation of B cells results in chronic activation of innate immune cells in neoplastic tissue thus promoting cell-cycle progression and survival
due to the activation of mast cells, granulocytes and macrophages and the factors from them released. Moreover the tumour microenvironment is enriched
in pro-inﬂammatory cytokines, chemokines, extracellular proteases and pro-angiogenic factors, such as TNFa, TGFb, VEGF, interleukin 1 (IL-1) and 6 (IL-6)
that contribute to neoplastic cell proliferation and survival. By contrast the activation of adaptive immunity leads to an antitumor effect through
T-cell-mediated toxicity in addition to antibody-dependent cell-mediated cytotoxicity and antibody-induced complement-mediated lysis.
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restore the normal levels of guard. Unbalance in the immune cells number in a particular district or tissue can dramatically
affect the maintenance of tissue homeostasis, such as occurs during tumor formation (Finch and Crimmins, 2004).
The existence of a link between immune cells and cancer has been known for many years (Balkwill and Mantovani, 2001),
even if their properly role is not well deﬁned.
Initially it was suggested that the inﬁltrate leukocyte could have a role in preventing the tumour growth, given the fact
that excessive inﬁltration of NKs in gastric and colorectal cancer was associated with favorable prognosis (Coca et al., 1997;
Ishigami et al., 2000). On the contrary the presence of other innate-immune cells within the tumour tissues such as macro-
phages in breast carcinoma, and mast cells in lung adenocarcinoma and melanoma, were associated with poor clinical prog-
nosis (Leek et al., 1996; Imada et al., 2000; Ribatti et al., 2003).
When colon tissue homeostasis is perturbed, several processes involved in the inﬂammation are induced, and if this phe-
nomenon is prolonged, so becoming chronic, it can bring to an excessive tissue remodeling, loss of its architecture or com-
pletely destruction, as well as induce DNA and protein damages because of the oxidative stress, intensifying the risk of
cancer.
The most prominent clinical evidence of a link between chronic inﬂammation and cancer arises from some epidemiolog-
ical studies, which claimed that long-term usage of anti-inﬂammatory drugs, such as aspirin and cyclooxygenase-2 (COX-2)
inhibitors, signiﬁcantly reduce the risk to get a cancer (Dannenberg and Subbaramaiah, 2003), including colorectal one (Rah-
me et al., 2003).
The inhibition of COX2, involved in the production of prostaglandin, seems to reduce cancer risk according to recent epi-
demiological studies (Zha et al., 2004). In several human epithelial cancers the COX2 over-expression, mainly found in stro-
mal cells, correlates with poor prognosis (Dannenberg and Subbaramaiah, 2003). The exact mechanism of action of the COX2
inhibitors is not yet entirely clear, but it seems to function by normalizing different pathways of stromal and innate immune
cells.
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the evidence of different proﬁles of immune status between healthy subjects and cancer affected patients. The latter exhibit
an enrichment in regulatory T-cells, at the expense of tumour-killing CD8+ CTL (Curiel et al., 2004). Neoplastic microenviron-
ments indeed seem to promote a chronic pro-tumorigenic inﬂammatory states rather than acute anti-tumour responses
(Zou, 2005).
Last but not least the tumour microenvironment is enriched in cytokines, chemokines, metalloproteinases and pro-angio-
genic factors, such as Tumour Necrosis Factor alfa (TNFa), TGFb, VEGF, interleukin 1 (IL-1) and 6 (IL-6), which contribute to
neoplastic cell proliferation and survival of damaged epithelial cells (Balkwill et al., 2005). In this context the matrix metallo-
proteinases (MMPs) play an important role, due to their capacity to remodel the ECM components and interfering with the
cell–cell and cell-matrix adhesions. Despite some MMPs are produced by epithelial cells, the major source of their produc-
tion are the stromal cell, such as ﬁbroblasts, vascular cells but also immune cells (Egeblad and Werb, 2002). MMP-9
and MMP-7 are the two major proteins of this family having a role in regulation of inﬂammation and tumour angiogenesis
(Bergers et al., 2000; Lynch et al., 2005) Fig. 4.6.1. Immunotherapy
All this advances carried out in recent years has fuelled many researcher group the purpose of developing new ap-
proaches of immunotherapy against tumours. The term ‘‘immunotherapy’’ indicates a treatment that includes the induction
and enhancement (immunotherapies), or the suppression of immune response (suppression immunotherapies).
Adoptive cell transfer (ACT) approach, involving the transfer of ex vivo expanded autologous or allogeneic tumour reac-
tive lymphocytes, has been reported to induce therapeutic efﬁcacy and increased patients survival when combined with
cytotoxic treatments (CTX, chemotherapy and radiotherapy). Ramakrishnan et al. demonstrated that CTX makes tumour
cells more susceptible to the cytolytic effect of cytotoxic T lymphocytes (CTLs), and that they are able to induce apoptosis
also in neighboring tumour cells that do not express speciﬁc tumour antigens (Ramakrishnan et al., 2010). These data sug-
gest that also a small numbers of CTLs could lead to a strong antitumor effect if combined with CTX.
Another important approach in tumour immunotherapy was sprouted from the idea to immunize patients against their
own cancer using tumour killed cells, proteins, peptides, or DNA vaccines, even if the success was limited (Amato et al., 2010;
Dougan and Dranoff, 2009; Giaccone et al., 2005; Testori et al., 2008).
As already mentioned the DCs are considered a bridge between innate and adaptive immunity. Early clinical trials showed
that the vaccination with ex vivo generated DCs pulsed with tumour antigens can be useful even if the clinical beneﬁt was
observed only in a small percentage of stage IV patients (Palucka et al., 2008). In some cases of soft tissue sarcoma, the intra-
tumoral treatment with DCs led to an increase in T-cell inﬁltration (Finkelstein et al., 2012), suggesting that the combined
vaccines of DCs and CTX can counteract its immunosuppression effect on tumour microenvironment.
Tregs targeting in combination with CTX could be very important advance in cancer treatment, since it is known that
enrichment of these cells into tumour microenvironment leads to block the anti-tumour immunity response, promoting also
malignant proliferation and dissemination of cell through the expression of soluble mediators (M}uzes et al., 2012). One of the
most efﬁcient strategies is based on CTL-4 inhibition. CTL-4 is a negative co-stimulatory molecule expressed on both T cells
and Tregs and it acts inhibiting T cells and at the same time promoting Tregs function. A monoclonal antibody blocking CTL-4,
ipilimumab, was recently recommended for the treatment of advanced malignant melanoma, displaying an extended overall
survival, correlating with an increase in T-cell activation and Tregs inhibition (Hodi et al., 2010) in combination with CTX im-
proved patient survival (Robert et al. 2011).
We have recently assessed that NKs can also play an important role in colon CSC recognition and killing (Tallerico et al.,
2013). NKs are potent cytotoxic lymphocytes that can recognize tumour cells, in particular CCSCs. We showed that this dif-
ferent susceptibility is due to a different expression of ligands for NKp30 and NKp44 within the natural cytotoxicity receptor
(NCR) group of activating NK receptors. The CCSCs express higher levels of these ligands and at the same time lower levels of
MHC class I, known to inhibit NK recognition. This study strengthens the idea of a therapy based on the conventional CTX
regimen (most effective on differentiated cells) coupled to NKs cells immunotherapy (speciﬁc for CSCs). Moreover it was re-
cently demonstrated that is possible to generate mature and functional NKs from several different human embryonic stem
cells (hESCs) and induced pluripotent stem cells (iPSCs). This innovative method could be extended to future studies improv-
ing clinical-scale expansion of anti-tumour lymphocytes (Knorr et al., 2013).
Most of the current strategies for immunotherapy aim to stimulation of the adaptive immune system dependent on
MHC-restricted ab T cells, even if their loss is often observed in cancer cells (Gattinoni et al., 2006; Vesely et al., 2011).
We have recently highlighted the crucial role of cd T lymphocytes on anticancer therapy, since they exhibit potent
MHC-unrestricted lytic activity against tumour cells (Todaro et al. 2009). In particular, this study emphasized the role of
aminobisphosphonates (N-BP), as well as the treatment with zoledronate promoting the activation and proliferation of
human Vc9Vd2. This subpopulation of T cells has been detected in the majority of CRC tumour inﬁltrating lymphocyte.
Moreover Vc9Vd2 T cells can be obtained from patient blood and ex vivo expanded (Bennouna et al., 2008; Kobayashi
et al., 2007), thus retaining their migration efﬁciency (Viey et al., 2008). Finally the cd T transfer concomitant with the
injection of bisphosphonates have been proved to be well tolerated and this fosters development of alternative, or better,
of adjuvant therapies for treatment of tumour patients, including CRC.
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Despite the improvements in cancer therapies and the application of new ‘‘target agents’’, the outlook for most of the pa-
tients is still poor, particularly in advanced solid tumours affected patients.
In the last years thanks to the increased diffusion of instruments for the proteomic and genomic characterization of tis-
sues, it was possible to deﬁne different subgroups of patients based on the genetic and biological alterations present into
colon tumour (De Sousa et al., 2013; Sadanandam et al., 2013). Each subtype shares similarities to distinct cell types of
the normal colon crypt, showing different degrees of stemness and Wnt signaling activity.
These classiﬁcations could be useful in clinical practice to predict the best regimen to adopt for each patient.
Another important approach for cancer treatment involves the culturing of freshly puriﬁed colon cancer cells to directly
test different combination of drugs. The idea to introduce individualized therapy harbored from the possibility to individu-
alize and select a small fraction of primary tumour cells with clonogenic capacity, the CSCs.
Three decades ago Salmon and Hamburger developed a culture method nowwell known as ‘‘clonogenic assay’’ or ‘‘human
tumour stem cell assay’’ (HTCA). This methodological approach allowed to culture single cell suspensions from primary tu-
mour in multilayer soft-agar and to treat the derived clone with speciﬁc drug (Salmon et al., 1978) introducing the concept of
target therapy.
Based on these observations several clinical trials have been carried out, often with surprising results. Von Hoff et al.
(1983) published a ﬁrst study based on HTCS experimental model as guidance for treatment of 470 patients with 27 different
advanced metastatic cancers (Von Hoff et al., 1983). They have found that the RR in the assay-guided therapy was 25%, com-
pared to the 14% in the empiric treatment group. A second randomized clinical trial was performed on 211 ovarian cancer
patients and it showed a higher RR in the assay-guided therapy (22%) compared to the empiric therapy group (3%) (Von Hoff
et al., 1991). However the selection of chemotherapy treatment based on in vitro drug sensitivity testing is not currently rec-
ommended outside the clinical trial setting (Samson et al., 2004; Schrag et al., 2004).8. The tumour heterogeneity puzzle
Despite the considerable progress made up on cancer research ﬁeld, to date the majority of patients does not seem to take
advantage of current therapies. These phenomena could be explained by tumour heterogeneity (Marusyk et al., 2012). The
intra-tumoral heterogeneity was ﬁrst proposed in the 70’s and justiﬁed by the continuous selection of dominant clones and
the differentiation of malignant stem cells, underling tumour progression and resistance to treatments.
The new treatment strategies based on advance technologies, always faster and cheaper, aim to characterize individual
tumour types reﬂecting a precise genomic/proteomic proﬁle and to couple them with the best available treatment.
To stress the heterogeneity concept Gerlinger et al. recently demonstrated that about two thirds of the mutations found in
single biopsies of renal cell carcinoma were not uniformly distributed throughout all the sample regions within the same
patient’s tumour (Gerlinger et al., 2012).
A key role in the maintenance of tumour heterogeneity it is certainly played by the surround microenvironment. Accord-
ing to the evolution principle, cells bringing different mutations should converge towards a common phenotype, able to
guarantee the cell growth within the tumour. The variable architecture of a tumour (vascularization, inﬁltration degree,
and connective tissue components) allows the selective growth of cell types carrying different mutations.
Since the majority of cancer-related mortality is due to the metastasis formation, and since most of the therapeutic deci-
sions are based on the primary tumour analysis, should be important to extend the phenotypic and genotypic analysis to the
metastatic foci (Stoecklein and Klein, 2010). Indeed, although metastatic lesions are related to primary tumours, sometimes
they can also carried additional mutations in functionally important loci completely absent in the primary site (Shah et al.,
2009; Yachida et al., 2010).9. Conclusions
In recent years there have been great efforts and have been collected a lot of information about the causes of the onset
and progression of CRC, but not always it has been found a direct application in the clinical setting, or sometimes the ex-
pected results in patients do not reﬂect those obtained in vitro or in various stages of clinical trials.
The different cell populations within the tumour mass not only restricted to the primary site, as well as the dual role of
the immune system against the tumour during its different evolution stages, and ﬁnally the diverse response to the treat-
ment of patients, highlight the urgency to obtain a higher resolution microscopic (molecular) analysis of the disease, without
giving up on a macroscopic view of the problem.
The future of cancer care lies surely in the individualized treatment of the disease, this approach requires, however, high-
er costs and dedicated and specialized staff, nowadays still under progress. It will be also necessary to develop faster and
more reliable study models than those currently considered valid for the study of this evil. For all these reasons. . .please
be ‘‘patient’’.
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